APVO - Company ID 0001671584
Aptevo Therapeutics Inc. trades as APVO. This page tracks Aptevo Therapeutics Inc. through 690 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Next research step
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Over the last 7 fiscal years Aptevo Therapeutics Inc.'s revenue declined from $33.60M to $3.11M, a compound annual decline rate of 28.8%. Net profit margin expanded from -1125.8% to 257.8% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-05-27 |
| Quarterly report | 10-Q | 2026-05-13 |
| Major company event | 8-K | 2026-05-13 |
| Major company event | 8-K | 2026-05-06 |
| Annual report | 10-K | 2026-03-26 |
| Major company event | 8-K | 2026-03-26 |
| Major company event | 8-K | 2026-03-11 |
| Major company event | 8-K | 2026-02-19 |
The largest companies sharing Aptevo Therapeutics Inc.'s SEC industry classification (pharmaceutical preparations).
In its latest fiscal year Aptevo Therapeutics Inc. reported a net loss of $25.97M.